{"DataElement":{"publicId":"11365394","version":"1","preferredName":"Immunosuppressive Therapy Administered Type","preferredDefinition":"A description of the immunosuppressive therapy that was administered.","longName":"IMMUNOSUP_THRPY_ADMIN_TY","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"4276945","version":"1","preferredName":"Immunosuppressive Therapy Administered","preferredDefinition":"Therapy used to decrease the body's immune response, such as drugs given to prevent transplant rejection._The act of having given something (e.g., a medication or test).","longName":"2854866v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2854866","version":"1","preferredName":"Immunosuppressive Therapy","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","longName":"C15261","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunosuppressive Therapy","conceptCode":"C15261","definition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65C9E4D1-CBFF-C2BB-E040-BB89AD430C4B","latestVersionIndicator":"Yes","beginDate":"2009-03-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-03-23","modifiedBy":"ONEDATA","dateModified":"2009-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7A29B03-E055-FD6D-E040-BB89AD435679","latestVersionIndicator":"Yes","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"KUMMEROA","dateModified":"2018-08-15","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5511066","version":"1","preferredName":"Immunosuppressive Therapy Type","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes._Type; a subdivision of a particular kind of thing.","longName":"5511066v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"150","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Tacrolimus","valueDescription":"Tacrolimus","ValueMeaning":{"publicId":"3305284","version":"1","preferredName":"Tacrolimus","longName":"3305284","preferredDefinition":"A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tacrolimus","conceptCode":"C1311","definition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-7062-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3EB2EF73-1A40-33B0-E053-F662850AB0D7","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"ONEDATA","dateModified":"2016-10-12","deletedIndicator":"No"},{"value":"Steroid","valueDescription":"Steroid","ValueMeaning":{"publicId":"5511067","version":"1","preferredName":"Steroid","longName":"5511067v1.00","preferredDefinition":"The use of exogenous steroids for the treatment of any disease or disorder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Steroid Therapy","conceptCode":"C15370","definition":"The use of exogenous steroids for the treatment of any disease or disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EB2EF73-1A4A-33B0-E053-F662850AB0D7","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3EB2EF73-1A63-33B0-E053-F662850AB0D7","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"ONEDATA","dateModified":"2016-10-12","deletedIndicator":"No"},{"value":"Sirolimus","valueDescription":"Sirolimus","ValueMeaning":{"publicId":"5127411","version":"1","preferredName":"Sirolimus","longName":"5127411","preferredDefinition":"A drug used to keep the body from rejecting organ and bone marrow transplants. Rapamune blocks certain white blood cells that can reject foreign tissues and organs. It also blocks a protein that is involved in cell division. It is a type of antibiotic, a type of immunosuppressant, and a type of serine/threonine kinase inhibitor. Rapamune was previously called rapamycin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA4E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3EB2EF73-1A6D-33B0-E053-F662850AB0D7","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"ONEDATA","dateModified":"2016-10-12","deletedIndicator":"No"},{"value":"Mycophenolate Mofetil (MMF)","valueDescription":"Mycophenolate Mofetil (MMF)","ValueMeaning":{"publicId":"5511068","version":"1","preferredName":"Mycophenolate Mofetil (MMF)","longName":"5511068v1.00","preferredDefinition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EB2EF73-1A77-33B0-E053-F662850AB0D7","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3EB2EF73-1A90-33B0-E053-F662850AB0D7","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"ONEDATA","dateModified":"2016-10-12","deletedIndicator":"No"},{"value":"Cyclosporine","valueDescription":"Cyclosporine","ValueMeaning":{"publicId":"3253643","version":"1","preferredName":"Cyclosporine","longName":"3253643","preferredDefinition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclosporine","conceptCode":"C406","definition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-7A3A-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3EB2EF73-1A9A-33B0-E053-F662850AB0D7","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"ONEDATA","dateModified":"2016-10-12","deletedIndicator":"No"},{"value":"Azathioprine","valueDescription":"Azathioprine","ValueMeaning":{"publicId":"3128751","version":"1","preferredName":"Azathioprine","longName":"3128751","preferredDefinition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azathioprine","conceptCode":"C290","definition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1F3C-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3EB2EF73-1AA4-33B0-E053-F662850AB0D7","beginDate":"2011-05-04","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"ONEDATA","dateModified":"2016-10-12","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3EB2EF73-1AAE-33B0-E053-F662850AB0D7","beginDate":"2011-05-04","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"ONEDATA","dateModified":"2016-10-12","deletedIndicator":"No"},{"value":"Solumedrol","valueDescription":"Solumedrol","ValueMeaning":{"publicId":"5678496","version":"1","preferredName":"Solumedrol","longName":"5678496v1.00","preferredDefinition":"The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone Sodium Succinate","conceptCode":"C48004","definition":"The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-7420-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-7439-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Ruxolitinib","valueDescription":"Ruxolitinib","ValueMeaning":{"publicId":"5125106","version":"1","preferredName":"Ruxolitinib","longName":"5125106","preferredDefinition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib","conceptCode":"C77888","definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A87E-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-7443-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Photopheresis (ECP)","valueDescription":"Photopheresis (ECP)","ValueMeaning":{"publicId":"5678497","version":"1","preferredName":"Photopheresis (ECP)","longName":"5678497v1.00","preferredDefinition":"A procedure which combines apheresis and photodynamic therapy, resulting in blood being treated with a photosensitizing agent and subsequently irradiated with specified wavelengths of light to achieve an effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extracorporeal Photopheresis","conceptCode":"C62729","definition":"A procedure which combines apheresis and photodynamic therapy, resulting in blood being treated with a photosensitizing agent and subsequently irradiated with specified wavelengths of light to achieve an effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-744D-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-7466-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Pentostatin","valueDescription":"Pentostatin","ValueMeaning":{"publicId":"5127413","version":"1","preferredName":"Pentostatin","longName":"5127413","preferredDefinition":"The active ingredient in a drug that is used to treat hairy cell leukemia and is being studied in the treatment of other types of cancer. Pentostatin blocks a protein needed for cell growth and may kill cancer cells. It is made by a bacterium. It is a type of adenosine deaminase inhibitor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentostatin","conceptCode":"C732","definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FAA7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-7470-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Budesonide","valueDescription":"Budesonide","ValueMeaning":{"publicId":"2576032","version":"1","preferredName":"Budesonide","longName":"2576032","preferredDefinition":"A glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Budesonide","conceptCode":"C1027","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon administration, budesonide binds to intracellular glucocorticoid receptors (GRs) and induces the expression of glucocorticoid-responsive genes that encode for anti-inflammatory mediators, such as certain anti-inflammatory cytokines, including interleukin 10 (IL-10), and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, budesonide prevents the release of pro-inflammatory cytokines from epithelial cells and macrophages, including interleukin 6 (IL-6), IL-8, interferon-beta (IFNb), and inhibits nuclear factor kappa-B (NF-kB) activation thereby decreasing NF-kB-mediated inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F60D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2012-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-747A-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Beclomethasone","valueDescription":"Beclomethosone","ValueMeaning":{"publicId":"5678498","version":"1","preferredName":"Beclomethasone","longName":"5678498v1.00","preferredDefinition":"The dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beclomethasone Dipropionate","conceptCode":"C299","definition":"The dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-7484-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-749D-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","deletedIndicator":"No"},{"value":"Anti-thymocyte globulin, rabbit","valueDescription":"Anti-thymocyte globulin, rabbit","ValueMeaning":{"publicId":"5678499","version":"1","preferredName":"Anti-thymocyte globulin, rabbit","longName":"5678499v1.00","preferredDefinition":"A preparation of purified, pasteurized, gamma globulin obtained by the immunization of rabbits with human thymocytes, with T-cell depleting and immunosuppressive activities. Upon administration, rabbit anti-thymocyte globulin (rATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which rATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion and reduction in T-cell activation and their cytotoxic activities. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease (GvHD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lapine T-Lymphocyte Immune Globulin","conceptCode":"C80833","definition":"A preparation of purified, pasteurized, gamma globulin obtained by the immunization of rabbits with human thymocytes, with T-cell depleting and immunosuppressive activities. Upon administration, rabbit anti-thymocyte globulin (rATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which rATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion and reduction in T-cell activation and their cytotoxic activities. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease (GvHD).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-74A7-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-74C0-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Anti-thymocyte globulin, horse","valueDescription":"Anti-thymocyte globulin, horse","ValueMeaning":{"publicId":"5678500","version":"1","preferredName":"Anti-thymocyte globulin, horse","longName":"5678500v1.00","preferredDefinition":"A purified, concentrated and sterile solution of horse-derived gamma globulin obtained by the immunization of horses with human T-lymphocytes, with T-cell depleting and immunosuppressive activities. Upon administration, horse anti-thymocyte globulin (hATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which hATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion, reduction in T-cell activation and modulation of their cytotoxic activities. Administering of hATG prior to transplantation may reduce the risk of graft-versus-host disease (GvHD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Equine Thymocyte Immune Globulin","conceptCode":"C80824","definition":"A purified, concentrated and sterile solution of horse-derived gamma globulin obtained by the immunization of horses with human T-lymphocytes, with T-cell depleting and immunosuppressive activities. Upon administration, horse anti-thymocyte globulin (hATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which hATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion, reduction in T-cell activation and modulation of their cytotoxic activities. Administering of hATG prior to transplantation may reduce the risk of graft-versus-host disease (GvHD).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-74CA-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-74E3-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Anti-TNF (Etanercept, Embrel)","valueDescription":"Anti-TNF (Etanercept, Embrel)","ValueMeaning":{"publicId":"5678501","version":"1","preferredName":"Anti-TNF (Etanercept, Embrel)","longName":"5678501v1.00","preferredDefinition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etanercept","conceptCode":"C2381","definition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-74ED-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-7506-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Anti-TNF (Infliximab, Remicade)","valueDescription":"Anti-TNF (Infliximab, Remicade)","ValueMeaning":{"publicId":"5678502","version":"1","preferredName":"Anti-TNF (Infliximab, Remicade)","longName":"5678502v1.00","preferredDefinition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infliximab","conceptCode":"C1789","definition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-7510-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-7529-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Anti-CD52 (Alemtuzumab, Campath)","valueDescription":"Anti-CD52 (Alemtuzumab, Campath)","ValueMeaning":{"publicId":"5678503","version":"1","preferredName":"Anti-CD52 (Alemtuzumab, Campath)","longName":"5678503v1.00","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-7533-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-754C-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Anti-CD25 (Zenapax, Daclizumab)","valueDescription":"Anti-CD25 (Zenepax, Daclizumab)","ValueMeaning":{"publicId":"5678504","version":"1","preferredName":"Anti-CD25 (Zenapax, Daclizumab)","longName":"5678504v1.00","preferredDefinition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daclizumab","conceptCode":"C1569","definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-7556-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-756F-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","deletedIndicator":"No"},{"value":"Anti-CD20 (Rituximab)","valueDescription":"Anti-CD20 (Rituximab)","ValueMeaning":{"publicId":"5678505","version":"1","preferredName":"Anti-CD20 (Rituximab)","longName":"5678505v1.00","preferredDefinition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-7579-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-7592-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EBAD08A-1995-69BF-E053-F662850A2434","beginDate":"2017-05-04","endDate":null,"createdBy":"HAMMA","dateCreated":"2017-05-04","modifiedBy":"ONEDATA","dateModified":"2017-05-04","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"6149013","version":"1","preferredName":"None","longName":"6149013v1.00","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68547E1A-4C9A-6A4E-E053-F662850A8A33","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"NELSONA","dateCreated":"2018-03-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68EA61EB-D315-1DEB-E053-F662850AC537","beginDate":"2018-04-02","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Rapamycin","valueDescription":"Rapamycin","ValueMeaning":{"publicId":"6160308","version":"1","preferredName":"Rapamycin","longName":"6160308","preferredDefinition":"Rapamycin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68EA61EB-D31F-1DEB-E053-F662850AC537","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68EA61EB-D338-1DEB-E053-F662850AC537","beginDate":"2018-04-02","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Induction agents","valueDescription":"Induction agents","ValueMeaning":{"publicId":"6160309","version":"1","preferredName":"Induction agents","longName":"6160309v1.00","preferredDefinition":"The first choice of treatment for a particular type of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Induction Therapy","conceptCode":"C158876","definition":"The first choice of treatment for a particular type of cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68EA61EB-D342-1DEB-E053-F662850AC537","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-04-02","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68EA61EB-D35B-1DEB-E053-F662850AC537","beginDate":"2018-04-02","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Everolimus","valueDescription":"Everolimus","ValueMeaning":{"publicId":"3379525","version":"1","preferredName":"Everolimus","longName":"3379525","preferredDefinition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3294-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0AD03F5-452D-38C9-E053-F662850A8263","beginDate":"2020-03-12","endDate":null,"createdBy":"GALITG","dateCreated":"2020-03-12","modifiedBy":"ONEDATA","dateModified":"2020-03-12","deletedIndicator":"No"},{"value":"IL-2","valueDescription":null,"ValueMeaning":{"publicId":"5235366","version":"1","preferredName":"Interleukin-2","longName":"5235366","preferredDefinition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3168829E-C941-6B0F-E050-BB89AD436CC0","latestVersionIndicator":"Yes","beginDate":"2016-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA26ADC7-8B5D-7678-E053-731AD00A7E3E","beginDate":"2022-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-03","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","deletedIndicator":"No"},{"value":"Belumosudil","valueDescription":null,"ValueMeaning":{"publicId":"7614732","version":"1","preferredName":"Belumosudil","longName":"7614732","preferredDefinition":"An orally administered inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belumosudil","conceptCode":"C128786","definition":"An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon oral administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses through the regulation of signal transducer and activator of transcription 3 and 5 (STAT3/STAT5) phosphorylation. This downregulates pro-inflammatory Th17 cells and increases regulatory T (Treg) cells. Belumosudil also inhibits ROCK2-mediated fibrotic processes, including stress fiber formation, myofibroblast activation and pro-fibrotic gene transcription. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F33BC-9A44-657F-E053-4EBD850AFD37","latestVersionIndicator":"Yes","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA4973DC-79A4-1F47-E053-731AD00A827A","beginDate":"2022-10-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-05","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","deletedIndicator":"No"},{"value":"Calcineurin inhibitor","valueDescription":null,"ValueMeaning":{"publicId":"11376864","version":"1","preferredName":"Calcineurin Inhibitor","longName":"11376864v1.00","preferredDefinition":"Any agent that inhibits calcineurin (protein phosphatase 3; PPP3), a serine/threonine protein phosphatase dependent on calcium and calmodulin, with immunosuppressant activity. Inhibition of calcineurin prevents dephosphorylation of the transcription factor nuclear factor of activated T-cells, cytoplasmic (NFATc), which prevents its translocation to the nucleus and the subsequent induction of the expression of interleukin-2 (IL-2). This prevents IL-2-mediated proliferation and activation of T-cells, and T-lymphocyte-mediated immune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcineurin Inhibitor","conceptCode":"C146638","definition":"Any agent that inhibits calcineurin (protein phosphatase 3; PPP3), a serine/threonine protein phosphatase dependent on calcium and calmodulin, with immunosuppressant activity. Inhibition of calcineurin prevents dephosphorylation of the transcription factor nuclear factor of activated T-cells, cytoplasmic (NFATc), which prevents its translocation to the nucleus and the subsequent induction of the expression of interleukin-2 (IL-2). This prevents IL-2-mediated proliferation and activation of T-cells, and T-lymphocyte-mediated immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA4973DC-79A3-1F47-E053-731AD00A827A","latestVersionIndicator":"Yes","beginDate":"2022-10-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-05","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA4973DC-79A5-1F47-E053-731AD00A827A","beginDate":"2022-10-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-05","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","deletedIndicator":"No"},{"value":"Ibrutinib","valueDescription":null,"ValueMeaning":{"publicId":"5588944","version":"1","preferredName":"Ibrutinib","longName":"5588944","preferredDefinition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibrutinib","conceptCode":"C81934","definition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B08557-93BA-6CD6-E053-F662850A558E","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA4973DC-79A6-1F47-E053-731AD00A827A","beginDate":"2022-10-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-05","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","deletedIndicator":"No"},{"value":"Methotrexate","valueDescription":null,"ValueMeaning":{"publicId":"5127393","version":"1","preferredName":"Methotrexate","longName":"5127393","preferredDefinition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F9D7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA4973DC-79A7-1F47-E053-731AD00A827A","beginDate":"2022-10-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-05","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","deletedIndicator":"No"},{"value":"Abatacept","valueDescription":null,"ValueMeaning":{"publicId":"6429536","version":"1","preferredName":"Abatacept","longName":"6429536","preferredDefinition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abatacept","conceptCode":"C28898","definition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AF6CD8-495C-4E44-E053-F662850AD113","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9A77E00-E2C3-6EF6-E053-731AD00A648E","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","deletedIndicator":"No"},{"value":"Methylprednisolone (Solumedrol)","valueDescription":null,"ValueMeaning":{"publicId":"6159937","version":"1","preferredName":"Methylprednisolone Sodium Succinate","longName":"6159937","preferredDefinition":"The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone Sodium Succinate","conceptCode":"C48004","definition":"The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AE1FEE-6037-3A56-E053-F662850AAD03","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9A77E00-E2C4-6EF6-E053-731AD00A648E","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","deletedIndicator":"No"},{"value":"Prednisone/prednisolone","valueDescription":null,"ValueMeaning":{"publicId":"13374558","version":"1","preferredName":"Prednisone And/Or Prednisolone","longName":"13374558v1.00","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations._Used to indicate that either or both of two items or options may be valid._A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prednisolone","conceptCode":"C769","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9A77E00-E2C2-6EF6-E053-731AD00A648E","latestVersionIndicator":"Yes","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9A77E00-E2C5-6EF6-E053-731AD00A648E","beginDate":"2023-04-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-18","modifiedBy":"GDEEN","dateModified":"2023-04-18","deletedIndicator":"No"},{"value":"Tacrolimus and MMF","valueDescription":null,"ValueMeaning":{"publicId":"14506196","version":"1","preferredName":"Tacrolimus And Mycophenolate Mofetil","longName":"14506196v1.00","preferredDefinition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tacrolimus","conceptCode":"C1311","definition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05F7CE10-768C-72D7-E063-731AD00A2671","latestVersionIndicator":"Yes","beginDate":"2023-09-22","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-22","modifiedBy":"MMADDINENI","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05F7CE10-768D-72D7-E063-731AD00A2671","beginDate":"2023-09-22","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-22","modifiedBy":"MMADDINENI","dateModified":"2023-09-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3233633","version":"1","preferredName":"Immunosuppressive Therapy Type","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes.:Type; a subdivision of a particular kind of thing.","longName":"C15261:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunosuppressive Therapy","conceptCode":"C15261","definition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A27C18C9-DBD6-820E-E040-BB89AD432300","latestVersionIndicator":"Yes","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-04","modifiedBy":"ONEDATA","dateModified":"2011-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EB2EF73-1A2A-33B0-E053-F662850AB0D7","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"MMADDINENI","dateModified":"2023-09-22","changeDescription":"Workflow and Registration Status Changed per Brenda Duggan; 05.16.18","administrativeNotes":"2022.10.3 Added missing concepts to PVs, changed RS from Incomplete to Application, no version needed per GD. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What type of immunosuppressive therapy was administered?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Which type of immunosuppressive medication other than steroid is patient currently taking?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Which type of immunosuppressive medication other than steroid has patient taken during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Immunosuppressive agent administered:","url":null,"context":"COG"},{"name":"DCP-TEXT-1","type":"Alternate Question Text","description":"Current Immunosuppressive Regimen","url":null,"context":"DCP"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA2676BE-C47F-7039-E053-731AD00A6243","latestVersionIndicator":"Yes","beginDate":"2022-10-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-03","modifiedBy":"MMADDINENI","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":"2022.10.3 Created for ticket request CADSR0001559. ak 2022.10.20 Reviewed and released. ak","unresolvedIssues":null,"deletedIndicator":"No"}}